RLD2102

RLD2102 is an investigational drug developed by Hanmi Pharmaceutical. It is a new molecular entity currently in early clinical development, with its mechanism of action and precise therapeutic class not yet disclosed. The drug has been studied in Phase 1 clinical trials primarily to assess safety and pharmacokinetics, including drug-drug interaction studies with other investigational agents (HCP1306 and RLD2302) in healthy volunteers. While the specific indication remains officially unspecified, some sources suggest it may be intended for the treatment of acute or chronic gastritis. No adverse events or FDA designations have been reported to date[1][2][3][4][5].

Other names

RLD2102RLD-2102RLD 2102